The surrogate outcome of progression free survival (PFS) can reliably predict overall survival (OS) in trials of immunotherapy for solid cancers, an Australian study has shown. Researchers at the NHMRC Clinical Trials Centre at the University of Sydney have developed a prediction model that uses 6-month PFS from the immunotherapy arm of randomised clinical trials ...
PFS can reliably predict OS in immunotherapy trials: NHMRC study
By Michael Woodhead
9 Sep 2020